TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients

TCR2 Therapeutics Inc. believes that its technology platform for the development of T-cell receptor (TCR)-based therapies can make the cancer treatments available to more patients, including people with solid tumors, and now it has $125m to take at least two candidates into the clinic.

Cambridge, Mass.-based TCR2 announced March 21 that it closed a Series B venture capital round to pursue clinical proof-of-concept for its platform. With the new round and its $44.5m Series A, the company has raised $169.5m since it emerged from stealth mode at the end of 2016